Diabetic Neuropathy Market Size USD 6,298.1 MN By 2031 Key Pharma Players Investing | Japan Updates - 2025

The Global Diabetic Neuropathy Market reached USD 3,775.4 million in 2022 and is projected to witness lucrative growth by reaching up to USD 6,298.1 million by 2031. The diabetic neuropathy market is expected to exhibit a CAGR of 6.7% during the forecast period (2024-2031).

Latest Japan News on Diabetic Neuropathy (2025)
In April 2025, a Japan-based pharmaceutical company, Ono Pharmaceutical, announced a Phase 2 clinical trial for a novel drug targeting painful diabetic peripheral neuropathy (DPN). The trial is focused on evaluating the safety and efficacy of a selective sodium channel blocker, showing promise in reducing nerve pain without central nervous system side effects.

Unlock exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://datamintelligence.com/download-sample/diabetic-neuropathy-market?kb

Diabetic Neuropathy Market Overview

Diabetic neuropathy refers to nerve damage caused by diabetes, often leading to pain, numbness, and weakness, primarily in the legs and feet. The market includes diagnostics, treatment options like pain relief medications, and ongoing R&D to manage or prevent nerve complications in diabetic patients.

Research Methodology:

The global Diabetic Neuropathy Market research report is based on a combination of primary and secondary data sources. The study carefully analyzes various factors influencing the industry, including government regulations, market dynamics, competitive landscape, historical trends, current conditions, and technological progress. It also evaluates future developments, related industry trends, market volatility, growth prospects, potential obstacles, and emerging challenges.

Segment Covered in the Diabetic Neuropathy Market:

By Type: Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy.

By Drug Class: Anti-Depressant, Anti-Convulsant, Opioids, NSAIDs, Others.

By Distribution Channel: Hospitals and Clinics Pharmacy, Retail Pharmacy and Stores, Online Pharmacy.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/diabetic-neuropathy-market?kb

List of the Key Players in the Diabetic Neuropathy Market:

Depomed pharma, Eli Lilly, Daiichi Sankyo, Teva Pharmaceutical Industries Ltd., Xenoport, Grünenthal, Johnson and Johnson, Pfizer, GlaxoSmithKline and Boehringer Ingelheim among others.

Industry Development:

In March 2022, Daiichi Sankyo Company Limited, a prominent global healthcare innovator, received regulatory approval in Japan to broaden the indications for its Tarlige Tablets (mirogabalin besilate). Initially approved for treating peripheral neuropathic pain, the new approval extends its use to cover a wider range of neuropathic pain conditions-enabling more patients to benefit from this effective analgesic therapy.

In July 2022, Teva Pharmaceutical Industries Ltd. and NeuroFront Therapeutics (Hong Kong) Limited announced a strategic collaboration through an exclusive licensing and commercialization agreement. This partnership aims to advance the development of NRD.E1, a novel non-opioid investigational drug originally developed by Novaremed. NRD.E1 is being explored as a treatment for diabetic neuropathic pain and other neuropathic pain disorders, representing a major step toward offering safer, non-opioid alternatives for chronic pain management.

Regional Analysis for Diabetic Neuropathy Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

The Report Includes:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Go-to-market Strategy.

➡ Neutral perspective on the market performance.

➡ Customized regional/country reports as per request and country level analysis.

➡ Potential & niche segments and regions exhibiting promising growth covered.

People Also Ask:

➠ What are the global sales, production, consumption, imports, and exports in the Diabetic Neuropathy market?

➠ Who are the top manufacturers, and what are their capacity, production, sales, pricing, and revenue stats?

➠ What key opportunities and challenges do vendors face in the Diabetic Neuropathy industry?

➠ Which product types, applications, or end-users are driving market growth, and what is their market share?

➠ What are the major growth drivers and restraints of the Diabetic Neuropathy market?

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.